SCHEMBL3524067

SCHEMBL3524067

COC(=O)c1cccc(Cn2cnc(OCc3ccccc3)c(Br)c2=O)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.56
MAPK10 P53779 1/20 0.50
YTHDC1 Q96MU7 1/20 0.48
MAPK8 P45983 1/20 0.46
MMP13 P45452 1/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
ABHD6 Q9BV23 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
OPRD1 P41143 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.43
MAPT P10636 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPK14 Q16539 1/20 0.43
CD74 P04233 1/20 0.43
MIF P14174 1/20 0.43
PPIA P62937 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3522861 0.90 MMP13 (0.53) MAPK10YTHDC1MMP13LMNAHPGD
SCHEMBL3523356 0.88 MAPK14 (0.45) IDO1YTHDC1MMP13MAPK14PPIA
SCHEMBL3519837 0.85 MAPK14 (0.54) IDO1LMNAMRGPRX4MAPTMAPK14
SCHEMBL4389849 0.82 MAPK14 (0.67) IDO1MAPK10MAPK8LMNAHPGD
SCHEMBL3524527 0.82 MAPK14 (0.60) LMNAHPGDKDM4EMAPK14
SCHEMBL3524427 0.81 MAPK14 (0.48) MAPK14
SCHEMBL3519707 0.81 MAPK14 (0.59) LMNAHPGDKDM4EMAPTMAPK14
SCHEMBL3520672 0.81 MAPK14 (0.51) MAPK10MMP13HPGDMAPK14
SCHEMBL3525260 0.80 SCD (0.47) MAPK10MAPK14
SCHEMBL3523400 0.79 MMP13 (0.50) MAPK10MMP13KDM4EMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795271-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2010-09-14 US disclosed
US-20090306108-A1 SUBSTITUTED PYRIMIDINONES PFIZER INC 2009-12-10 US disclosed
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES PHARMACIA CORPORATION (US) 2007-07-19 US disclosed
US-7183287-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2007-02-27 US disclosed
US-20040242608-A1 Substituted pyrimidinones PHARMACIA LLC 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306108-A1 SUBSTITUTED PYRIMIDINONES MAPK1, MAP3K8, MAP3K7 IDO1 1603/4885MAPK10 26/4885YTHDC1 4595/4885
US-20040242608-A1 Substituted pyrimidinones MAPK1, MAPK7, MAP3K8 IDO1 1482/4885MAPK10 23/4885YTHDC1 4713/4885
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES MAPK1, MAP3K8, MAP3K7 IDO1 1603/4885MAPK10 26/4885YTHDC1 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.